\[[PubMed: 27373187](https://pubmed.ncbi.nlm.nih.gov/27373187)\] 77. Pasrija C, Kronfli A, Rouse M, Raithel M, Bittle GJ, Pousatis S, Ghoreishi M, Gammie JS, Griffith BP, Sanchez PG, Kon ZN. Outcomes after surgical pulmonary embolectomy for acute submassive and massive pulmonary embolism: A single-center experience. J Thorac Cardiovasc Surg. 2018 Mar;155(3):1095-1106.e2. \[[PubMed: 29452460](https://pubmed.ncbi.nlm.nih.gov/29452460)\] 78. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22. \[[PubMed: 16009794](https://pubmed.ncbi.nlm.nih.gov/16009794)\] 79. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P., Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003 Jul 01;139(1):19-25. \[[PubMed: 12834314](https://pubmed.ncbi.nlm.nih.gov/12834314)\] 80. Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ. 2007 Mar 31;334(7595):674. \[[PMC free article: PMC1839169](/pmc/articles/PMC1839169/)\] \[[PubMed: 17289685](https://pubmed.ncbi.nlm.nih.gov/17289685)\] 81. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, LÃ¤rfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995 Jun 22;332(25):1661-5. \[[PubMed: 7760866](https://pubmed.ncbi.nlm.nih.gov/7760866)\] 82. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Hirsh J, Kearon C. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24;342:d3036. \[[PMC free article: PMC3100759](/pmc/articles/PMC3100759/)\] \[[PubMed: 21610040](https://pubmed.ncbi.nlm.nih.gov/21610040)\] 83. Poli D, Miniati M. The incidence of recurrent venous thromboembolism and chronic thromboembolic pulmonary hypertension following a first episode of pulmonary embolism. Curr Opin Pulm Med. 2011 Sep;17(5):392-7. \[[PubMed: 21743331](https://pubmed.ncbi.nlm.nih.gov/21743331)\] 84. Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-2023. \[[PubMed: 29746227](https://pubmed.ncbi.nlm.nih.gov/29746227)\] 85. Rezende SM. Barriers in the diagnosis of pulmonary embolism. Lancet Haematol.